Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC
From BeiGene
Via Business Wire
News headline image
The Gift Chinese Regulators Just Gave Tech Stocks Like Alibaba And BeiGene ↗
Auditing issues persist for some 270 companies trading in the U.S. But they could ease. 
Via Investor's Business Daily
News headline image
Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework ↗
 
Via Benzinga
News headline image
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs ↗
As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China. 
Via InvestorPlace
News headline image
BeiGene: Q4 Earnings Insights ↗
BeiGene (NASDAQ:BGNE) reported its Q4 earnings results on Friday, February 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
CStone's Commercialization Capacity Put to Test With Latest Drug Approval ↗
Key takeaways: 
Via Benzinga
News headline image
Which Chinese Stocks Could Get Delisted? 6 Companies to Watch. ↗
Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way. 
Via InvestorPlace
News headline image
Analyst Ratings For BeiGene ↗
Over the past 3 months, 4 analysts have published their opinion on BeiGene (NASDAQ:BGNE) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2022 ↗
Upgrades Loop Capital upgraded the previous rating for Aspen Technology Inc (NASDAQ:AZPN) from Hold to Buy. In the second quarter, Aspen Technology showed an EPS of $1.20,... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Thursday ↗
Keybanc cut the price target on Darden Restaurants, Inc. (NYSE: DRI) from $170 to $160. Darden shares rose 0.1% to $129.69 in pre-market trading. RBC Capital lowered Union... 
Via Benzinga
News headline image
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
From BeiGene
Via Business Wire
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
News headline image
Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today? ↗
Chinese stock delisting news today has several big names in the country seeing their shares slip on fears they could be next. 
Via InvestorPlace
News headline image
What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today ↗
Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ: HCM... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Valneva Says Confident Of Conditional Approval For COVID Vaccine Candidate In... 
Via Benzinga
News headline image
Chinese Stocks Are Falling: What's Going On? ↗
Shares of multiple Chinese companies are trading lower Thursday following reports the U.S. Securities and Exchange Commision has identified multiple US-listed ADRs as... 
Via Benzinga
News headline image
Why BeiGene — And 2 Other China-Based Biotechs — Are In Trouble ↗
The SEC is calling out a several stocks for non-compliance. Could they face delisting? 
Via Investor's Business Daily
News headline image
Zai Lab Revenue Triples, As It Struggles To Break Cycle Of Mounting Losses ↗
Key takeaways: Zai Lab reported its revenue grew 194% last year, but its loss also increased by 162% as it spent heavily on R&D and marketing The company hopes heavy R&D... 
Via Benzinga
News headline image
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis... 
Via Benzinga
News headline image
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene's Brukinsa Applications Under FDA, European Review For Leukemia ↗
The European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for... 
Via Benzinga
News headline image
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia
From BeiGene
Via Business Wire
News headline image
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma
From BeiGene
Via Business Wire
News headline image
BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia
From BeiGene
Via Business Wire
News headline image
BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference
From BeiGene, Ltd.
Via Business Wire
News headline image
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
From BeiGene
Via Business Wire
News headline image
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation
From BeiGene
Via Business Wire
News headline image
Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies ↗
Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model, in which mice develop their own... 
Via Benzinga
News headline image
New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report ↗
Investors kept a close look at China’s solar and wind power stocks last year, but were least interested in the hobbled education sector By Bamboo Works team Chinese concept... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.